Concord Biotech Limited

Concord Biotech experienced a challenging FY26, marked by a 12% revenue degrowth for the full year and a 24% decline in Q4, primarily due to industry headwinds^🌐, geopolitical issues, and supply chain disruption^🌐s. API revenues fell by 12% to INR 829 crores for FY26, while formulation revenues saw an 8% decline in Q4 and 13% for the full year. Profit after tax was significantly impacted, dropping 30% to INR 260 crores for the year.

Despite financial setbacks, the company strengthened its regulatory compliance, successfully completing US FDA, EU GMP, Russian GMP, NAFDAC, and WHO-GMP inspections across multiple facilities. The injectable facility commenced operations and achieved WHO-GMP certification, positioning it for domestic market entry and contract manufacturing. Concord also commercialized Fusidic Acid and initiated API supplies to two innovator companies, contributing to future growth.

Geopolitical uncertainties in the Middle East and delays in obtaining CDSCO approvals significantly impacted revenue, restricting European supplies for nearly three months and deferring an INR 25 crores US Veterans Affairs tender. These issues led to a shift in customer procurement strategies towards more staggered approaches and increased inventory days to 480, up from 286 in the prior year, affecting working capital.

Concord Biotech maintains a strong financial position as a zero-debt company, holding over INR 414 crores in cash and equivalents as of March 31, 2026. FY26 capex stood at INR 65 crores, with future general capex projected at INR 20-30 crores annually. The company's existing manufacturing capacities are deemed sufficient to support a peak revenue potential of INR 3,000 crores, with additional capex for a soft gel facility and an innovator project.

Management expresses confidence in a stronger FY27, anticipating revenue growth 'slightly better off' than the historical 18%, starting from Q1. This growth is expected to be driven by new product launches like Nystatin and Fusidic Acid, increased market share in anti-infective and oncology segments, and operating leverage from new ventures like Stellon Biotech and the injectable facility, which are projected to reach breakeven in FY27.

The company expects EBITDA margin improvement in FY27, with a 1-1.5% positive impact from solar plant savings and additional benefits from operating leverage as new businesses ramp up. While gross margins are expected to remain in a similar range, the normalization of inventory and resolution of geopolitical issues are anticipated to further support profitability, with overall EBITDA margins potentially moving closer to the 1.5% mark from power and fuel improvements.